Stocks Health care CDIO
NASDAQ · Health careCardio Diagnostics Holdings, Inc. (CDIO)
Cardio Diagnostics Holdings, Inc. brought in $14.5K of revenue over the twelve months to June 30, 2026, down 25.9% from a year earlier. It posted a net loss of $6.5M. In fiscal 2025 capital spending exceeded operating cash flow by $5.9M. At June 30, 2026 it held $0 in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2026.
What Cardio Diagnostics Holdings, Inc. does
Cardio Diagnostics Holdings, Inc. is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker CDIO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $14.8K | -$6.5M | -$3.71 | -$5.9M |
| 2024 | $34.9K | -$8.4M | -$9.35 | -$5.2M |
| 2023 | $17.1K | -$8.4M | -$19.91 | -$6.2M |
| 2022 | $950 | -$4.7M | -$45.54 | n/a |
| 2021 | $901 | -$620.4K | -$15.99 | n/a |
Full financial statements: income, balance sheet and cash flow
Where CDIO ranks in Health care
Latest SEC filings
What Cardio Diagnostics Holdings, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 18, 2026
- September 8, 2026Additional proxy material DEFA14A
- August 20, 2026
- August 7, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 28% to $5.4K versus the same quarter last year; diluted EPS -$0.51 versus -$0.97.
- August 7, 2026Additional proxy material DEFA14A
- August 5, 2026Proxy statement DEF 14A
- July 23, 2026
- July 13, 2026Preliminary proxy statement PRE 14A
- May 15, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 185% to $2.7K versus the same quarter last year; diluted EPS -$0.63 versus -$0.97.
- March 13, 2026Annual report 10-K · period to December 31, 2025Revenue fell 58% to $14.8K versus the prior year; diluted EPS -$3.71 versus -$9.35.
Insider trades
What the people running Cardio Diagnostics Holdings, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Questions about CDIO
What does Cardio Diagnostics Holdings, Inc. do?
Cardio Diagnostics Holdings, Inc. is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker CDIO.
Is Cardio Diagnostics Holdings, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $6.5M on revenue of $14.5K.
How much revenue does Cardio Diagnostics Holdings, Inc. make?
Over the twelve months to June 30, 2026 Cardio Diagnostics Holdings, Inc. reported revenue of $14.5K. That is 25.9% less than a year earlier.
When did Cardio Diagnostics Holdings, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the shareholder vote results from September 18, 2026.
Similar companies
Compare CDIO with
Follow CDIO
Get an email when Cardio Diagnostics Holdings, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow CDIO: get an email when it filesWhere the numbers come from
Financial figures are the values Cardio Diagnostics Holdings, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.